CLINICAL_TRIALS
trial_result
· 2007-12-05
Clinical Trial Update: Study Comparing Bioavailability of Oral Formulations of Vabicaserin [Phase 1]
Summary
A Phase 1 bioavailability study comparing oral formulations of vabicaserin in schizophrenia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED